Kevin Hur

2 days ago | onlinelibrary.wiley.com | Jaynelle Gao |Ryan Chung |Jason Chwa |Kevin Hur

1 Introduction Immune checkpoint inhibitors (ICIs), which suppress immune checkpoint receptor-ligand binding to promote T-cell activation and antitumor immunity [1], have been increasingly utilized in recent years, becoming the standard of care for approximately 8% of head and neck cancers in 2020 [1-3].